Resultados de la búsqueda 391-400 of 12305 for Visceral leishmaniasis

1. Hematología - Ensayos clínicos - Mayo Clinic

   The purpose of this study is to determine adverse events and change in disease symptoms of ABBV-383 in adult participants with relapsed/refractory (R/R) MM.

2. Hematología - Ensayos clínicos - Mayo Clinic

   Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior ...

3. Hematología - Ensayos clínicos - Mayo Clinic

   Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, ...

4. Cirugía - Ensayos clínicos - Mayo Clinic

   Pituitary tumor registry ... Rochester, Minn. The purpose of this data registry involves the collection of standard of care clinical treatment regimens, ...

5. Hematología - Ensayos clínicos - Mayo Clinic

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

6. Cirugía - Ensayos clínicos - Mayo Clinic

   Imperforate Anus, also known as anal atresia, is a rare birth defect. Unable to pass stool through the gastrointestinal tract, this condition can result in ...

7. Cirugía - Ensayos clínicos - Mayo Clinic

   The purpose of this study is to combine recent advances in ultrasound imaging, specifically an endonasal transducer array and contrast enhanced ultrasound, ...

8. Carcinoma hepatocelular

   Hepatocellular carcinoma. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1514. Accessed July 25, 2025.

9. Hematología - Ensayos clínicos - Mayo Clinic

   Rochester, Minn. The purpose of this study is to determine how well tafasitamab, lenalidomide and venetoclax work in treating patients with mantle cell lymphoma ...

10. Hematología - Ensayos clínicos - Mayo Clinic

    All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...